December 7, 2016: Thursday is shaping up to be one of the most important days for Biogen in recent memory, as the Cambridge biotech prepares to announce data from a trial of a potentially groundbreaking Alzheimer’s drug.
December 7, 2016: A $50M investment will push basic science discoveries from Gladstone toward cures for heart disease. A new biopharma company, Tenaya Therapeutics, will build on discoveries in cardiovascular disease research made at the Gladstone Institutes.
December 7, 2016: As 2016 draws to a close, we all tend to look back on the good and the bad experienced during another trip around the sun. Unfortunately for Gilead, there were plenty of bad things that happened this year. Some of the bad news was just the reality of doing business in the biotech world, including several clinical failures.
December 7, 2016: Britain's competition watchdog has fined Pfizer a record $107M for its role in ramping up the cost of an epilepsy drug by as much as 2,600 percent.